SEARCH

SEARCH BY CITATION

Keywords:

  • HPV;
  • EGFR;
  • LOH;
  • HNSCC;
  • squamous cell carcinoma

Abstract

As our understanding of HNSCC increases so has biomarker development. HPV16 integration is a significant marker of favorable prognosis and response to therapy for HNSCC. EGFR-amplification and overexpression is a poor-prognostic indicator. For premalignant lesions, LOH of 3p&9p21 loci confers an elevated risk of malignant transformation. As molecular targets are identified, these will be candidates for biomarkers for detection, diagnosis, prognosis, and therapy. Validation of these biomarkers requires demonstration of independence of significance beyond known biomarkers. J. Surg. Oncol. 2008;97:640–643. © 2008 Wiley-Liss, Inc.